Neuro-Oncology · 13 Nov 2026
Defining and managing NF1-related peripheral nerve sheath tumors at risk for malignant transformation: Consensus from the Atypical Neurofibroma Symposium
Carlos G Romo, Shivani Ahlawat, Kimberly K Amrami, Allan J Belzberg, Jaishri O Blakeley, Miriam A Bredella, Prashant Chittiboina, Heike Daldrup-Link, Eva Dombi, Laura Fayad, Rosalie E Ferner, Michael J Fisher, Kristina E Hawk, Angela C Hirbe, Fabian M Johnston, AeRang Kim, Bruce Korf, Adam Levin, Ina Ly, Carol D Morris, Mark Murphey, Christine A Pratilas, Marcus Ratley, Inka Ristow, Steven Sheard, Benjamin Siegel, Dave Viskochil, Brian D Weiss, Lennart Well, Brigitte C Widemann, Yin Wu, Andrea M Gross, the Symposium on Atypical Neurofibroma: State of the Science Members
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Abstract People with neurofibromatosis type 1 (NF1) are at risk for developing peripheral nerve sheath tumors (PNSTs) ranging from benign neurofibromas to high-grade sarcomas. PNSTs known as atypical neurofibromas are at increased risk for malignant transformation. In 2017 the term ANNUBP (atypical neurofibromatous neoplasm of uncertain biologic potential) was proposed for PNSTs at increased risk for malignant transformation based on histopathologic features. Subsequently it was recognized that PNSTs not meeting ANNUBP criteria could still have concerning clinical, imaging and molecular features. A State of the Science conference addressed how to define these pre-cancerous PNSTs and reached consensus regarding clinical management and priority areas of research. Key recommendations from this symposium include: (1) using a combination of histologic, molecular and imaging features to define pre-malignant “at-risk” PNST; (2) recognizing that people with NF1 may be divided into “higher-risk” and “average-risk” for MPNST based on features such as their germline NF1 variant, internal tumor burden and history of malignancy or radiotherapy and; (3) the need to validate consensus screening and surveillance strategies based on personal and tumor-related risk factors. These recommendations will advance the ability to standardize care, and potentially fuel research that enables early diagnosis, prevention of malignant transformation and improved outcomes.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (0)
What it cites, from open citation data, with Crossref's record of each.